The rs10830963 Variant in Interaction with Pre-Pregnancy BMI is a Pharmacogenetic Marker for the Initiation of Antenatal Insulin Therapy in Gestational Diabetes Mellitus.

The rs10830963 variant of the () gene is associated with the development of gestational diabetes mellitus (GDM). We hypothesized that carrying the rs10830963/ risk allele had effect on antenatal insulin therapy (AIT) initiation in GDM in a body mass index (BMI)-dependent manner. : In this post hoc analysis the rs10830963 genotype and the clinical data of 211 Caucasian GDM patients were assessed.